Samuel Alito gives stay of execution in Missouri – a look at the case

Samuel Alito granted a stay of execution for Russell Bucklew, convicted of killing a man in 1996. The case is under consideration because Missouri refuses to name the supplier of its execution drug, and because Bucklew has been diagnosed with a rare congenital disease.

Jeff Roberson/AP
A group of death penalty opponents hold a vigil outside St. Francis Xavier College Church hours before the scheduled execution of Missouri death row inmate Russell Bucklew May 20, in St. Louis. A federal appeals court has granted a stay of execution for Bucklew, hours before he was scheduled to die for killing a southeast Missouri man in 1996.

Missouri's seventh execution in seven months, and the nation's first since one went awry in Oklahoma, was on hold after U.S. Supreme Court Justice Samuel Alito granted a stay of execution.

Missouri Attorney General Chris Koster said the full Supreme Court is expected to weigh the inmate's appeal on Wednesday. If the court rejects the appeal, Missouri could still carry out the execution on Wednesday. Inmate appeals have targeted Missouri's secretive execution process, which does not reveal the state's source of lethal drugs. There is new attention on Missouri's execution after Oklahoma put executions on hold amid an investigation into what caused an inmate's vein to collapse during his lethal injection. Here are details about the case:



Russell Bucklew, 46, stole a car, guns and handcuffs from his police officer brother in March 1996 and tracked down his ex-girlfriend, Stephanie Pruitt. He killed the man she was living with, Michael Sanders, at Sanders' mobile home. He kidnapped Pruitt, drove to a remote area and raped her, then got into a shootout with a Missouri State trooper. He escaped jail and attacked Pruitt's mother with a hammer before he was finally jailed for good.



Missouri uses a single-drug injection of the sedative pentobarbital. The state switched to pentobarbital late last year after previously using a three-drug method. Missouri has executed six inmates with pentobarbital since November. Bucklew would be the seventh.



There are two and they are related. Like many states, Missouri refuses to name the supplier of its execution drug and will not say whether the drug has undergone quality testing. Attorneys for Bucklew and other death row inmates contend that if they don't know what's in the drug, who made it or where it was tested, it is impossible to know that inmates wouldn't be subjected to agonizing pain during executions that would violate the constitutional ban on cruel and unusual punishment. Bucklew also suffers from a rare congenital disease that causes weakened and malformed blood vessels and has impaired circulation.



Oklahoma has a three-drug lethal injection method that includes the drugs midazolam, vecuronium bromide and potassium chloride — all potent drugs with potentially serious side effects. Midazolam is a short-acting sedative sometimes used to calm patients before medical procedures or before surgery involving general anesthesia. Vecuronium bromide is a muscle relaxant and used during some surgeries. Potassium chloride is used to treat potassium deficiency but is used in executions to stop the heart.



Inmate Clayton Lockett writhed on the gurney, gritted his teeth, lifted his head several times and moaned before dying of an apparent heart attack 43 minutes after the start of his execution on April 29.

A doctor inside the death chamber reported Lockett's vein had collapsed and some of the lethal drugs were absorbed into his tissue or leaked out. The prison system director then called off the execution, but Lockett died about 10 minutes later. A state report showed Lockett had an intravenous tap placed at his groin because suitable veins couldn't be found elsewhere in his body.

Oklahoma has put executions on hold while an investigation is ongoing, but authorities have suggested the trouble started with Lockett's vein rather than the drugs. Many defense attorneys, meanwhile, say the incident bolsters calls for greater execution drug transparency.



Death penalty opponents have pressured drug manufacturers, many of them in Europe where capital punishment opposition is strong, to withhold sales of their products from U.S. prison and corrections agencies for use in the death penalty.

You've read  of  free articles. Subscribe to continue.

Dear Reader,

About a year ago, I happened upon this statement about the Monitor in the Harvard Business Review – under the charming heading of “do things that don’t interest you”:

“Many things that end up” being meaningful, writes social scientist Joseph Grenny, “have come from conference workshops, articles, or online videos that began as a chore and ended with an insight. My work in Kenya, for example, was heavily influenced by a Christian Science Monitor article I had forced myself to read 10 years earlier. Sometimes, we call things ‘boring’ simply because they lie outside the box we are currently in.”

If you were to come up with a punchline to a joke about the Monitor, that would probably be it. We’re seen as being global, fair, insightful, and perhaps a bit too earnest. We’re the bran muffin of journalism.

But you know what? We change lives. And I’m going to argue that we change lives precisely because we force open that too-small box that most human beings think they live in.

The Monitor is a peculiar little publication that’s hard for the world to figure out. We’re run by a church, but we’re not only for church members and we’re not about converting people. We’re known as being fair even as the world becomes as polarized as at any time since the newspaper’s founding in 1908.

We have a mission beyond circulation, we want to bridge divides. We’re about kicking down the door of thought everywhere and saying, “You are bigger and more capable than you realize. And we can prove it.”

If you’re looking for bran muffin journalism, you can subscribe to the Monitor for $15. You’ll get the Monitor Weekly magazine, the Monitor Daily email, and unlimited access to